

Form PTO-1449	U.S. Department of Commerce, Patent and Trademark Office	ATTY. DOCKET NO. P50438-1C1	SERIAL NO. Not assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Blackburn et al.	
		FILING DATE Herewith	GROUP Not assigned

1050 U.S. PRO
09/965099
09/26/99

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PAD	AA	5,387,581	2/7/95	Odawara, et al.	514	165	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No	
PAD	AB	0 388 914 A1	9/26/90	EPO	C12P	21/08		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PAD	AC	Bajaj et al., "A Monoclonal Antibody to Factor IX That Inhibits the Factor VIII:Ca Potentiation of Factor X Activation", <i>J. Biol. Chem.</i> , Vol. 260, No. 21, pp. 11574-11580 (1985)
	AD	Bajaj et al., "Antibody-Probed Conformational Transitions in the Protease Domain of Human Factor IX Upon Calcium Binding and Zymogen Activation: Putative High-Affinity Ca ²⁺ -Binding Site in the Protease Domain", <i>Proc. Natl. Acad. Sci., USA</i> , Vol. 89, pp. 152-156 (1992)
	AE	Cheung et al., "Localization of a Calcium-Dependent Epitope to the Amino Terminal Region of the GLA Domain of Human Factor IX", <i>Thrombosis Research</i> , Vol. 81, No. 1, pp. 65-73 (1996)
	AF	Church et al., "An Inhibitory Monoclonal Antibody to Factor X that Blocks Prothombin Activation but not Prothrombinase Enzyme Assembly", <i>Blood</i> , Vol. 72, No. 6 (December), pp. 1911-1921 (1988)
	AG	Donath et al., "Kinetics of Factor VIII Light-Chain Cleavage by Thrombin and Factor Xa", <i>Eur. J. Biochem.</i> , Vol. 240, pp. 365-372 (1996)
	AH	Frazier et al., "Mapping of Monoclonal Antibodies to Human Factor IX", <i>Blood</i> , Vol. 74, No. 3 pp. 971-977 (1989)
	AI	Fulcher et al., "Localization of Human Factor FVIII Inhibitor Epitopes to Two Polypeptide Fragments", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82, pp. 7728-7732 (1985)
	AJ	Healey et al., "Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII", <i>J. Biol. Chem.</i> , Vol. 270, No. 24, pp. 14505-14509 (1995)
	AK	Hoffman et al., "Factors IXa and Xa Play Distinct Roles in Tissue Factor-Dependent Initiation of Coagulation", <i>Blood</i> , Vol. 86, No. 5, pp. 1794-1801 (1995)
	AL	L. Hoyer and D. Scandella, "Factor VIII Inhibitors: Structure and Function in Autoantibody and Hemophilia A Patients", <i>Seminars in Hematology</i> , Vol. 31, No. 2, Suppl. 4, pp. 1-5 (1994)
	AM	Jenny et al., "Immunochemical Techniques for Studying Coagulation Proteins", <i>Methods in Enzymology</i> , Vol. 222, pp. 400-416 (1993)
	AN	Larson et al., "Structural Integrity of the γ -Carboxyglutamic Acid Domain of Human Blood Coagulation Factor IXa is Required for Its Binding to Cofactor VIIIa", <i>J. Biol. Chem.</i> , Vol. 271, No. 7, pp. 3869-3876 (1996)

EXAMINER

PATRICIA A. DUFFY

DATE CONSIDERED

4/4/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50438-1C1	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Blackburn et al.	
		FILING DATE Herewith	GROUP Not assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PAD	AO	Leyte et al., "Inhibition of Human Coagulation Factor VIII by Monoclonal Antibodies", <i>J. Biochem.</i> , Vol. 263, pp. 187-194 (1989)
	AP	Lollar et al., "Inhibition of Human Factor VIIIa by Anti-A2 Subunit Antibodies", <i>J. Clin. Invest.</i> , Vol. 93, pp. 2497-2504 (1994)
	AQ	J. Loscalzo and A. Schafer, "Factor VIII and Other Coagulation Factor Inhibitors", <i>Thrombosis and Hemorrhage</i> , Chapter 37, pp. 729-747 (1994)
	AR	Lubin et al., "Elimination of a Major Inhibitor Epitope in Factor VIII", <i>J. Biol. Chem.</i> , Vol. 269, No. 12, pp. 8639-8641 (1994)
	AS	Quellette, et al., "Neutralization of Factor X Activity by Factor X-Specific Monoclonal Antibodies", <i>Blood Coagulation and Fibrinolysis</i> , Vol. 3, pp. 563-574 (1992)
	AT	Saenko et al., "Slowed Release of Thrombin-Cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition", <i>J. Biol. Chem.</i> , Vol. 271, No. 44, pp. 27424-27431 (1996)
	AU	D. Scandella, "Human Antibodies Which Inactivate Factor VIII: Their Epitope Specificity and Biochemical and Functional Characteristics", <i>International Journal of Pediatric Hematology/Oncology</i> , Vol. 1, pp. 437-447 (1994)
	AV	D. Scandella, "Human Anti-Factor VIII Antibodies: Epitope Localization and Inhibitory Function", <i>Vox Sanguinis</i> , Vol. 70 (suppl 1), pp. 9-14 (1996)
	AW	Sinha et al., "Functional Characterization of Human Blood Coagulation Factor XIa Using Hybridoma Antibodies", <i>J. of Biol. Chem.</i> , Vol. 260, No. 19, pp. 10714-10719 (1985)
	AX	Schnogen et al., "Acquired Factor VIII Inhibitors in Nonhemophilic Patients", <i>Ann Hematol.</i> , Vol. 74, pp. 89-93 (1997)
	AY	Sugahara et al., "Isolation and Characterization of Canine Factor IX", <i>Thrombosis and Haemostasis</i> , Vol. 75(3), pp. 450-455 (1966)
✓	AZ	Tiarks et al., "Factor VIII Epitopes Recognized with Inhibitory Monoclonal Antibodies", <i>Acta Haematol</i> , Vol. 83, pp. 69-75 (1990)
EXAMINER PATRICIA A DUFFY		DATE CONSIDERED 4/4/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. P50438-1C1	SERIAL NO. Not assigned
	APPLICANT Blackburn et al.	
	FILING DATE July 1, 1999	GROUP Not assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PAD	BA	Abstracts, "Thrombosis and Haemostasis", <i>J. International Society on Thrombosis and Haemostasis</i> , Vol. 69(6), p. 1239, Abstract 2485 (1993)
	BB	Bessos et al., "The Characterization of a Panel of Monoclonal Antibodies to Human Coagulation Factor IX", <i>Thrombosis Research</i> , Vol. 40, pp. 863-867 (1985)
	BC	Biedmond et al., "Complete Inhibition of Endotoxin-Induced Coagulation Activation in Chimpanzees With a Monoclonal Fab Fragment Against Factor VII/VIIa", <i>Thrombosis and Haemostasis</i> , Vol. 73, No. 1, pp. 223-230 (1995)
	BD	F. Desposito and Y. Arkel, "Inhibitors of Coagulation in Children", <i>Critical Reviews in Oncology/Hematology</i> , Vol. 7, No. 1, pp. 53-69 (1987)
	BE	Griffin et al., "The Production and Characterisation of a Panel of Ten Murine Monoclonal Antibodies to Human Procoagulant Factor VIII", <i>Thrombosis and Haemostasis</i> , Vol. 55 (1), pp. 40-46 (1986)
	BF	S. Morrison, "In Vitro Antibodies: Strategies for Production and Application", <i>Annu. Rev. Immunol.</i> , Vol. 10, pp. 239-65 (1992)
	BG	Warrier et al., "Safety of High Doses of a Monoclonal Antibody-Purified Factor IX Concentrate", <i>American Journal of Hematology</i> , Vol. 49, pp. 92-94 (1995)
	BH	Lenting et al., "A Novel Antithrombotic Strategy Based on Inhibitors of Factor VIII-Factor IX Complex Assembly", <i>Thrombosis and Hemostasis</i> , June Supplement, p. 689 (1997)
	BI	Lenting et al., "The Sequence Glu ¹⁸¹¹ -Lys ¹⁸¹⁸ of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX", <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 4, pp. 1935-1940 (1996)
	BJ	Lenting et al., "Identification of a Binding Site for Blood Coagulation Factor IXa on the Light Chain of Human Factor VIII", <i>The Journal of Biological Chemistry</i> , Vol. 269, No. 10, pp. 7150-7155 (1994)
	BK	L. Stryer, <i>Biochemistry</i> , W.H. Freeman and Company, San Francisco, 1981, pp. 512-513
↓	BL	Kasai et al., "Molecular Cloning of Murine Monoclonal Anti-idiotypic Fab", <i>Journal of Immunological Methods</i> , Vol. 155, pp. 77-89 (1992)

EXAMINER

PATRICIA A-DUFFY

DATE CONSIDERED

4/4/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. P50438-1C1	SERIAL NO. Not assigned
	APPLICANT Blackburn et al.	
	FILING DATE Herewith	GROUP Not assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PAD	BM	Fang et al., "Human Rheumatoid actors with Restrictive Specificity for Rabbit Immunoglobulin G: Auto- and Multi-reactivity, Diverse ... V \wedge IIIb", <i>J. Exp. Med.</i> , Vol. 179, pp. 1445-1456 (1994)
	BN	Silberstein et al., "Relationship of Variable Region Genes Expressed by a Human B Cell Autoantibodies", <i>J. Exp. Med.</i> , Vol. 169, pp. 1631-1643 (1989)
	BO	Pascual, et al., "The Complete Nucleotide Sequences of the Heavy Chain Regions ... Rheumatoid ; Arthritis", <i>J. Clin. Invest.</i> , Vol. 86, pp. 1320-1328 (1990)
	BP	Roark, et al., "Breakdown of B Cell Tolerance in a Mouse Model of Systemic Lupus Erythematosus", <i>J. Exp. Med.</i> , Vol. 181, pp. 1157-1167 (1995)
	BQ	S. Stark and A. Caton, "Antibodies That Are Specific for a Single Amino Acid Interchange in a Protein Epitope Use Structurally Distinct Variable Regions", <i>J. Exp. Med.</i> , Vol. 174, pp. 613-624 (1991)
	BR	Minnema et al., "Enhancement of Rabbit Jugular Vein Thrombolysis by Neutralization of Factor XI", <i>J. Clin. Invest.</i> , Vol. 101, pp. 10-14 (1998)
	BS	C. Granger, "Heparin Management in Acute Myocardial Infarction (AMI)", <i>Aust NZ J Med</i> , Vol. 28, pp. 541-547 (1998)
	BT	Watkins et al., "Determinants of Rebound Thrombin Activity After Cessation of Heparin in Patients Undergoing Coronary Interventions", <i>Catheterization and Cardiovascular Diagnosis</i> , Vol. 44, pp. 257-264 (1998)
	BU	Cannon et al., "TNK-Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction", <i>Circulation</i> , Vol. 98, No. 25, pp. 2805-14 (1998)
	BV	K. Tachias and E. Madison, "Variants of Tissue-type Plasminogen Activator That Display Extraordinary ... Plasminogen Activator Inhibitor Type 1", <i>The Journal of Biological Chemistry</i> , Vol 272, No. 23, pp. 14580-14585 (1997)
↓	BW	Fujise et al., "A Tissue Plasminogen Activator/P-Selectin Fusion Protein Is an Effective Thrombolytic Agent", <i>Circulation</i> , Vol. 95, pp. 715-722 (1997)

EXAMINER	DATE CONSIDERED
PATRICIA A. DUFFY	4/4/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50438-1C1	SERIAL NO. Not assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Blackburn et al.	
		FILING DATE Herewith	GROUP Not assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PAD	BX	Van de Werf, et al., Safety Assessment of Single-bolus Administration of TNK Tissue-plasminogen ... The Assent-1 trial", Clinical Investigation, <i>American Heart Journal</i> , Vol. 137, No. 5, pp. 786-791 (1999)
	BY	Coombs et al., "Directing Sequence-specific Proteolysis to New Targets", <i>The Journal of Biological Chemistry</i> , Vol. 273, No. 8, pp. 4323-4828 (1998)
	BZ	Granger et al., "Thrombin Generation, Inhibition and Clinical Outcomes in Patients Results From the GUSTO-I Trial", <i>JACC</i> , Vol. 31, No. 3, pp. 597-505 (1998)
	CA	Granger, et al., "Rebound Increase in Thrombin Generation and Activity After Cessation of Intravenous Heparin Coronary Syndromes", <i>Circulation</i> , Vol. 91, pp. 1929-1935 (1995)
	CB	Bouma et al., "Factor XI and Protection of the Fibrin Clot Against Lysis - A Role for the Intrinsic Pathway of Coagulation in Fibrinolysis", <i>Thromb. Haemost.</i> , Vol. 80, pp. 24-27 (1998)
	CC	Bovill et al., "Hemorrhagic Events during Therapy with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin Myocardial Infarction", <i>Ann. Intern. Med.</i> , Vol. 115(4), pp. 256-265 (1991)
	CD	Becker et al., "Molecular Basis for the Resistance of Fibrin-bound Thrombin to Inactivation By Heparin/Serpin Complexes", In: <i>Chemistry and Biology of Serpins</i> , eds., Chuch et al., Plenum Press, New York, pp. 55-66 (1997)
	CE	Neuhaus et al., "Improved Thrombolysis in Acute Myocardial ... of Alteplase: Results of the rt-PA-APSAC Patency Study (TAPS)", <i>JACC</i> , Vol. 19, No. 5, pp. 885-891 (1992)
	CF	Rao et al., "Thrombolysis in Myocardial Infarction ... With Recombinant Tissue Plasminogen Activator and Streptokinase", <i>JACC</i> , Vol. 11, No. 1, pp. 1-11 (1988)
↓	CG	E. Topol, "The Future of Antithrombotic and Antiplatelet Therapy for Ischemic Heart Disease", <i>American Heart Journal</i> , Vol. 135, pp. S66-S68 (1998)

EXAMINER

PATRICIA A. DUFFY

DATE CONSIDERED

4/4/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.